Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatments by being less toxic and improving the survival of cancer patients. The greatest challenge to their success is the resistance exhibited by cancer patients. However, the potential of microRNAs (miRNAs) for sensitizing molecules to TKIs has been well recognized, with several reports publishing promising results. Nonetheless, this therapeutic window faces challenges and several often-overlooked limitations. One of the most fundamental challenges is selecting the optimal miRNA candidates for clinical trials, as miRNAs are promiscuous and regulate hundreds of targets. In this review, we describe how miRNAs enhance sensitivity to TKIs across various types of cancer. We highlight several challenges and limitations in achieving a successful collaboration between small molecules (TKIs-miRNAs). Our focus is on proposing a workflow to select the most suitable miRNA candidate, recommending several available bioinformatics tools to develop a successful therapeutic partnership between TKIs and miRNAs. We hope that this initial proposal will provide valuable support for future research.